Inspired by these successful recent cases, in this study we further improved the computational and experimental workflow to search for T790M-mutant EGFR inhibitors, which we believe will likely constitute a novel treatment of EGFR TKI-resistant lung cancer. This evidence concerns the gene EGFR and lung carcinoma.